Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Pancreatic Neoplasms 7Colorectal Neoplasms 6Small Cell Lung Carcinoma 3Stomach Neoplasms 2Solid Tumor Cancer 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Rectal Cancer Patients 1PDAC - Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Neoadjuvant Chemotherapy 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Efficacy and Safety 1Carcinoma, Ovarian Epithelial 1Advanced Small Intestine Cancer 1

Interventions

surufatinib 1irinotecan sucrosofate 1envafolimab 1anlotinib 1Vincristine 1Temozolomide 1Proton Therapy 1Positron Emission Tomography Computed Tomography 1Neoadjuvant Therapy 1Methotrexate 1Ifosfamide 1Etoposide 1Epirubicin 1Drug Therapy 1Brachytherapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Osteosarcoma × irinotecan sucrosofate × Clear all
NCT07444918 2026-03-03

Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
33 enrolled
Sarcoma

Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡